Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+biologics

94 Results

Sort By:

Manipulation of Regulatory T Cell and DC Function by Targeting Neuritin Gene Using Antibodies, Agonists and Antagonists

Unmet NeedThe recent breakthroughs in immuno-oncology have changed the way that researchers think about treating autoimmune diseases and cancer by modulating the immune system. Regulatory T cells (Treg) limit autoimmunity but also attenuate the potency of antitumor immunity. Enhancement of Treg function could treat autoimmune diseases while the inhibition...

Published: 6/26/2025 | Inventor(s): Drew Pardoll, Joseph Barbi, Fan Pan, Hong Yu, Ching-Tai Huang, Xiaoyu Pan, Charles Drake, Jonathan Powell

Keywords(s): Antibodies, Biologics, Cancers, Disease Indication, Immunotherapy, Infectious Diseases, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics

Novel monoclonal antibody inhibitors targeting potassium channel KCNK9

Unmet Need:KCNK9 is one of 15 mammalian subtypes in the highly conserved family of two-pore domain potassium channels (K2P). Under physiological conditions, KCNK9 is primarily expressed in the brain where it serves to maintain cellular membrane potentials. However, overexpression of KCNK9 has been detected in breast, lung, skin, and other cancers, and...

Published: 6/26/2025 | Inventor(s): John Laterra, Han Sun, Min Li, Amy Fulton

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Lung Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Respiratory Diseases, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Oncology > Lung Cancer

A Novel and Unique Set of Human Antibodies to Human Resistin and to Human Resitin-like Molecule Beta (RELMB) that can be used to Target these Proteins in Human Disease

Unmet NeedAutoinflammatory responses, your body’s innate defense mechanism against infections and stressors, can become overactive and cause chronic inflammation in various tissues and organs. Inflammatory diseases affect more than 200 million people worldwide and include pulmonary hypertension, scleroderma, rheumatoid arthritis, pulmonary fibrosis,...

Published: 6/26/2025 | Inventor(s): Roger Johns

Keywords(s): Antibodies, Biologics, Cardiovascular Diseases, Disease Indication, Hypertension, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Cardiovascular > Hypertension

CRISPR/Cas9 and Tumor-Specific Guide RNAs as a Specific and Selective Cancer Cell Killing Biologic Platform

Value Proposition:Specific targeting of mutations can treat any cancer with the specified mutations.Selective cell killing spares healthy tissue while eliminating cancer cells. Pan-cancer efficacy as guide RNAs are developed to target a wide breadth of cancer-specific mutations.Lack of protospacer adjacent motif (PAM) sites in healthy host cells prevents...

Published: 6/27/2025 | Inventor(s): James Eshleman, Selina Shiqing Teh, Kirsten Bowland, Nicholas Roberts

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Research Tools > Nucleic Acids

Cell-Permeable Protein Therapeutic for Pain and Itch

Novelty:Identification of a mutant peptide with strong inhibitory effect on nociceptor TRPA1, useful for the prevention and treatment of chronic and acute pain and itch.Value Proposition:Dysregulation of ion channels is associated with various debilitating conditions, including chronic pain and itch. Transient receptor potential ankyrin 1 (TRPA1), an...

Published: 6/26/2025 | Inventor(s): Hao-Jui Weng, Xinzhong Dong

Keywords(s): Biologics, Biomarker, Chronic Pain, CNS and Neurological Disorders, Disease Indication, Mechanism of Action Biomarker, Peptide, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Pain, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Pain > Chronic Pain

Transgenic Fungi that Kill Malaria Parasites in Mosquitoes

Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. Value Proposition: Unmodified, Metarhizium anisopliae kills mosquitoes slowly. If mosquitoes are infected by the...

Published: 6/26/2025 | Inventor(s): Raymond St. Leger, Angray Kang, Weiguo Fang, Marcelo Jacobs-Lorena

Keywords(s): Biologics, Disease Indication, Disease Management System, Healthcare Management, Infectious Diseases, Malaria, Operations Management, Parasitic Infections, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Computers, Electronics & Software > Clinical Management, Technology Classifications > Computers, Electronics & Software > Healthcare IT, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Computers, Electronics & Software, Clinical and Disease Specializations > Infectious Diseases, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Infectious Diseases > Malaria, Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections

Engineered Cytokine-antibody Fusion for Targeted Expansion of Immune Effector Cells

Unmet NeedGlobal revenue from the cytokine therapeutics market was valued at approximately $16.5 billion in 2018, and cytokine immunotherapy is a promising field of anti-cancer treatments for a broad range of cancer types. In particular, interleukin-2 (IL-2) therapy is shown to stimulate anti-cancer immunity. However, IL-2 activates contradictory immune...

Published: 6/27/2025 | Inventor(s): Jamie Spangler, Jakub Tomala, Michael Leff, Seth Ludwig, Elissa Leonard, Marek Kovar, Jirina Kovarova

Keywords(s): Biologics, Cancers, Disease Indication, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Biologics

Bioreducible Poly(beta-amino ester)s for siRNA Delivery

C12218: Efficient Delivery Vehicle for Controlled Gene Knockdown Novelty: This technology comprises the use of bioreducible polymer based nanoparticle system that can release siRNA cargo to the cytoplasm of cells to knockdown target gene expression in tissues. Value Proposition: Gene therapy is a developing medical field and there is a need for...

Published: 6/26/2025 | Inventor(s): Kristen Kozielski, Stephany Tzeng, Jordan Green

Keywords(s): Biologics, Brain Cancer, Cancers, Cell Therapy, Disease Indication, Drug Delivery Vehicle, Glioma, Nucleic Acid, Polymers, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Cell Therapies, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Glioma

Albumin-Flt3L Fusion Protein to Enhance Anti-Tumor Immunity and Antigen-specific T-cell Cytotoxicity

Unmet Need: Active immunotherapy, such as anti-PD-1/PD-L1 and anti-CTLA-4 checkpoint blockage, involves the administration of molecules to mobilize host immune cells to recognize and kill tumors. Proper presentation of tumor antigens through antigen presenting cells is a prerequisite to elicit a potent immune response. Current strategies enhance antigen...

Published: 6/27/2025 | Inventor(s): T.c. Wu, Chien-Fu Hung, Brandon Lam

Keywords(s): Biologics, Cancers, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Research Instrument, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Clinical and Disease Specializations > Immunology, Technology Classifications, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Targets

Antisense oligonucleotide therapy and biomarker assay for C9ORF72 hexanucleotide expansion disorders

Therapy to Treat and Assay to Monitor Neurodegenerative Disease JHU REF: [C12195]Invention novelty: This technology is the use of antisense oligonucleotides (ASO) as a therapeutic for specific neurodegenerative diseases. The technology could also be used in development of a biomarker assay to monitor the efficacy of the ASO therapy. Value Proposition: Current...

Published: 6/26/2025 | Inventor(s): Christopher Donnelly, C. Bennett, Susan Freier, Rita Sattler, Jeffrey Rothstein

Keywords(s): Amyotrophic Lateral Sclerosis, Assay, Biologics, Clinical Diagnostics, CNS and Neurological Disorders, Dementia, Disease Indication, In Vitro Diagnostics, Neurodegeneration, Nucleic Acid, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Neurology, Technology Classifications > Research Tools, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Clinical and Disease Specializations > Neurology > Neurodegeneration

1 2 3 4 5 6 7 8 9 10